Fate Therapeutics, UC San Diego Launch CAR NK Cancer Immunotherapy Collaboration

Fate Therapeutics said today it will develop off-the-shelf, chimeric antigen receptor (CAR)-targeted natural killer (NK) cell cancer immunotherapies through a research collaboration with the University of California, San Diego.The collaboration—whose value was not disclosed—will be led by Dan S. Kaufman, M.D., Ph.D., director of cell therapy at UC San Diego School of Medicine and a professor of medicine in the school’s Division of Regenerative Medicine.On November 30, Dr. Kaufm